INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26701, 11160, 'Tamsulosin', 'Hypotension', 'Peripheral alpha 1- adrenergic receptor blocking agents (aka alpha 1- blockers) cause vasodilation and can produce marked hypotension, especially orthostatic hypotension with syncope or other postural symptoms such as dizziness, lightheadedness, and palpitations.  Orthostatic effects are most common during initiation of therapy and often occur within 90 minutes after the first dose.  However, they can also occur following a dosage increase or resumption of therapy after an interruption of more than a few days.  Agents with alpha 1a specificity, such as tamsulosin, act primarily on the prostate but are not devoid of hypotensive effects.  Therapy with peripheral alpha-1 blockers should be administered cautiously in patients with or predisposed to hypotensive or syncopal episodes.  Caution is also advised in patients who are dehydrated (e.g., due to severe or prolonged diarrhea or vomiting), since they may be more sensitive to the hypotensive effect of the drugs.  Therapy should be initiated with the lowest dosage possible and titrated gradually based on patient response and tolerance in accordance with the individual product package labeling.  During initiation or reinstitution of therapy and following an increase in dosage, patients should be advised not to rise abruptly from a sitting or recumbent position and to avoid situations where injury could result if syncope occur.  Concomitant use of alcohol, extensive periods of standing, prolonged or intense exercise, and exposure to heat can also precipitate orthostatic hypotension and should be minimized.  If dizziness, lightheadedness or palpitations occur, the patient should sit or lie down, and seek medical attention if symptoms are recurrent or bothersome.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26702, 11161, 'Tamsulosin', 'Hypotension', 'Peripheral alpha 1- adrenergic receptor blocking agents (aka alpha 1- blockers) cause vasodilation and can produce marked hypotension, especially orthostatic hypotension with syncope or other postural symptoms such as dizziness, lightheadedness, and palpitations.  Orthostatic effects are most common during initiation of therapy and often occur within 90 minutes after the first dose.  However, they can also occur following a dosage increase or resumption of therapy after an interruption of more than a few days.  Agents with alpha 1a specificity, such as tamsulosin, act primarily on the prostate but are not devoid of hypotensive effects.  Therapy with peripheral alpha-1 blockers should be administered cautiously in patients with or predisposed to hypotensive or syncopal episodes.  Caution is also advised in patients who are dehydrated (e.g., due to severe or prolonged diarrhea or vomiting), since they may be more sensitive to the hypotensive effect of the drugs.  Therapy should be initiated with the lowest dosage possible and titrated gradually based on patient response and tolerance in accordance with the individual product package labeling.  During initiation or reinstitution of therapy and following an increase in dosage, patients should be advised not to rise abruptly from a sitting or recumbent position and to avoid situations where injury could result if syncope occur.  Concomitant use of alcohol, extensive periods of standing, prolonged or intense exercise, and exposure to heat can also precipitate orthostatic hypotension and should be minimized.  If dizziness, lightheadedness or palpitations occur, the patient should sit or lie down, and seek medical attention if symptoms are recurrent or bothersome.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26703, 11162, 'Tamsulosin', 'Hypotension', 'Peripheral alpha 1- adrenergic receptor blocking agents (aka alpha 1- blockers) cause vasodilation and can produce marked hypotension, especially orthostatic hypotension with syncope or other postural symptoms such as dizziness, lightheadedness, and palpitations.  Orthostatic effects are most common during initiation of therapy and often occur within 90 minutes after the first dose.  However, they can also occur following a dosage increase or resumption of therapy after an interruption of more than a few days.  Agents with alpha 1a specificity, such as tamsulosin, act primarily on the prostate but are not devoid of hypotensive effects.  Therapy with peripheral alpha-1 blockers should be administered cautiously in patients with or predisposed to hypotensive or syncopal episodes.  Caution is also advised in patients who are dehydrated (e.g., due to severe or prolonged diarrhea or vomiting), since they may be more sensitive to the hypotensive effect of the drugs.  Therapy should be initiated with the lowest dosage possible and titrated gradually based on patient response and tolerance in accordance with the individual product package labeling.  During initiation or reinstitution of therapy and following an increase in dosage, patients should be advised not to rise abruptly from a sitting or recumbent position and to avoid situations where injury could result if syncope occur.  Concomitant use of alcohol, extensive periods of standing, prolonged or intense exercise, and exposure to heat can also precipitate orthostatic hypotension and should be minimized.  If dizziness, lightheadedness or palpitations occur, the patient should sit or lie down, and seek medical attention if symptoms are recurrent or bothersome.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26704, 15376, 'Tamsulosin', 'Hypotension', 'Peripheral alpha 1- adrenergic receptor blocking agents (aka alpha 1- blockers) cause vasodilation and can produce marked hypotension, especially orthostatic hypotension with syncope or other postural symptoms such as dizziness, lightheadedness, and palpitations.  Orthostatic effects are most common during initiation of therapy and often occur within 90 minutes after the first dose.  However, they can also occur following a dosage increase or resumption of therapy after an interruption of more than a few days.  Agents with alpha 1a specificity, such as tamsulosin, act primarily on the prostate but are not devoid of hypotensive effects.  Therapy with peripheral alpha-1 blockers should be administered cautiously in patients with or predisposed to hypotensive or syncopal episodes.  Caution is also advised in patients who are dehydrated (e.g., due to severe or prolonged diarrhea or vomiting), since they may be more sensitive to the hypotensive effect of the drugs.  Therapy should be initiated with the lowest dosage possible and titrated gradually based on patient response and tolerance in accordance with the individual product package labeling.  During initiation or reinstitution of therapy and following an increase in dosage, patients should be advised not to rise abruptly from a sitting or recumbent position and to avoid situations where injury could result if syncope occur.  Concomitant use of alcohol, extensive periods of standing, prolonged or intense exercise, and exposure to heat can also precipitate orthostatic hypotension and should be minimized.  If dizziness, lightheadedness or palpitations occur, the patient should sit or lie down, and seek medical attention if symptoms are recurrent or bothersome.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26705, 16953, 'Tamsulosin', 'Hypotension', 'Peripheral alpha 1- adrenergic receptor blocking agents (aka alpha 1- blockers) cause vasodilation and can produce marked hypotension, especially orthostatic hypotension with syncope or other postural symptoms such as dizziness, lightheadedness, and palpitations.  Orthostatic effects are most common during initiation of therapy and often occur within 90 minutes after the first dose.  However, they can also occur following a dosage increase or resumption of therapy after an interruption of more than a few days.  Agents with alpha 1a specificity, such as tamsulosin, act primarily on the prostate but are not devoid of hypotensive effects.  Therapy with peripheral alpha-1 blockers should be administered cautiously in patients with or predisposed to hypotensive or syncopal episodes.  Caution is also advised in patients who are dehydrated (e.g., due to severe or prolonged diarrhea or vomiting), since they may be more sensitive to the hypotensive effect of the drugs.  Therapy should be initiated with the lowest dosage possible and titrated gradually based on patient response and tolerance in accordance with the individual product package labeling.  During initiation or reinstitution of therapy and following an increase in dosage, patients should be advised not to rise abruptly from a sitting or recumbent position and to avoid situations where injury could result if syncope occur.  Concomitant use of alcohol, extensive periods of standing, prolonged or intense exercise, and exposure to heat can also precipitate orthostatic hypotension and should be minimized.  If dizziness, lightheadedness or palpitations occur, the patient should sit or lie down, and seek medical attention if symptoms are recurrent or bothersome.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26706, 21318, 'Tamsulosin', 'Hypotension', 'Peripheral alpha 1- adrenergic receptor blocking agents (aka alpha 1- blockers) cause vasodilation and can produce marked hypotension, especially orthostatic hypotension with syncope or other postural symptoms such as dizziness, lightheadedness, and palpitations.  Orthostatic effects are most common during initiation of therapy and often occur within 90 minutes after the first dose.  However, they can also occur following a dosage increase or resumption of therapy after an interruption of more than a few days.  Agents with alpha 1a specificity, such as tamsulosin, act primarily on the prostate but are not devoid of hypotensive effects.  Therapy with peripheral alpha-1 blockers should be administered cautiously in patients with or predisposed to hypotensive or syncopal episodes.  Caution is also advised in patients who are dehydrated (e.g., due to severe or prolonged diarrhea or vomiting), since they may be more sensitive to the hypotensive effect of the drugs.  Therapy should be initiated with the lowest dosage possible and titrated gradually based on patient response and tolerance in accordance with the individual product package labeling.  During initiation or reinstitution of therapy and following an increase in dosage, patients should be advised not to rise abruptly from a sitting or recumbent position and to avoid situations where injury could result if syncope occur.  Concomitant use of alcohol, extensive periods of standing, prolonged or intense exercise, and exposure to heat can also precipitate orthostatic hypotension and should be minimized.  If dizziness, lightheadedness or palpitations occur, the patient should sit or lie down, and seek medical attention if symptoms are recurrent or bothersome.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26707, 22063, 'Tamsulosin', 'Hypotension', 'Peripheral alpha 1- adrenergic receptor blocking agents (aka alpha 1- blockers) cause vasodilation and can produce marked hypotension, especially orthostatic hypotension with syncope or other postural symptoms such as dizziness, lightheadedness, and palpitations.  Orthostatic effects are most common during initiation of therapy and often occur within 90 minutes after the first dose.  However, they can also occur following a dosage increase or resumption of therapy after an interruption of more than a few days.  Agents with alpha 1a specificity, such as tamsulosin, act primarily on the prostate but are not devoid of hypotensive effects.  Therapy with peripheral alpha-1 blockers should be administered cautiously in patients with or predisposed to hypotensive or syncopal episodes.  Caution is also advised in patients who are dehydrated (e.g., due to severe or prolonged diarrhea or vomiting), since they may be more sensitive to the hypotensive effect of the drugs.  Therapy should be initiated with the lowest dosage possible and titrated gradually based on patient response and tolerance in accordance with the individual product package labeling.  During initiation or reinstitution of therapy and following an increase in dosage, patients should be advised not to rise abruptly from a sitting or recumbent position and to avoid situations where injury could result if syncope occur.  Concomitant use of alcohol, extensive periods of standing, prolonged or intense exercise, and exposure to heat can also precipitate orthostatic hypotension and should be minimized.  If dizziness, lightheadedness or palpitations occur, the patient should sit or lie down, and seek medical attention if symptoms are recurrent or bothersome.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26708, 22204, 'Tamsulosin', 'Hypotension', 'Peripheral alpha 1- adrenergic receptor blocking agents (aka alpha 1- blockers) cause vasodilation and can produce marked hypotension, especially orthostatic hypotension with syncope or other postural symptoms such as dizziness, lightheadedness, and palpitations.  Orthostatic effects are most common during initiation of therapy and often occur within 90 minutes after the first dose.  However, they can also occur following a dosage increase or resumption of therapy after an interruption of more than a few days.  Agents with alpha 1a specificity, such as tamsulosin, act primarily on the prostate but are not devoid of hypotensive effects.  Therapy with peripheral alpha-1 blockers should be administered cautiously in patients with or predisposed to hypotensive or syncopal episodes.  Caution is also advised in patients who are dehydrated (e.g., due to severe or prolonged diarrhea or vomiting), since they may be more sensitive to the hypotensive effect of the drugs.  Therapy should be initiated with the lowest dosage possible and titrated gradually based on patient response and tolerance in accordance with the individual product package labeling.  During initiation or reinstitution of therapy and following an increase in dosage, patients should be advised not to rise abruptly from a sitting or recumbent position and to avoid situations where injury could result if syncope occur.  Concomitant use of alcohol, extensive periods of standing, prolonged or intense exercise, and exposure to heat can also precipitate orthostatic hypotension and should be minimized.  If dizziness, lightheadedness or palpitations occur, the patient should sit or lie down, and seek medical attention if symptoms are recurrent or bothersome.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26709, 27871, 'Tamsulosin', 'Hypotension', 'Peripheral alpha 1- adrenergic receptor blocking agents (aka alpha 1- blockers) cause vasodilation and can produce marked hypotension, especially orthostatic hypotension with syncope or other postural symptoms such as dizziness, lightheadedness, and palpitations.  Orthostatic effects are most common during initiation of therapy and often occur within 90 minutes after the first dose.  However, they can also occur following a dosage increase or resumption of therapy after an interruption of more than a few days.  Agents with alpha 1a specificity, such as tamsulosin, act primarily on the prostate but are not devoid of hypotensive effects.  Therapy with peripheral alpha-1 blockers should be administered cautiously in patients with or predisposed to hypotensive or syncopal episodes.  Caution is also advised in patients who are dehydrated (e.g., due to severe or prolonged diarrhea or vomiting), since they may be more sensitive to the hypotensive effect of the drugs.  Therapy should be initiated with the lowest dosage possible and titrated gradually based on patient response and tolerance in accordance with the individual product package labeling.  During initiation or reinstitution of therapy and following an increase in dosage, patients should be advised not to rise abruptly from a sitting or recumbent position and to avoid situations where injury could result if syncope occur.  Concomitant use of alcohol, extensive periods of standing, prolonged or intense exercise, and exposure to heat can also precipitate orthostatic hypotension and should be minimized.  If dizziness, lightheadedness or palpitations occur, the patient should sit or lie down, and seek medical attention if symptoms are recurrent or bothersome.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26710, 27890, 'Tamsulosin', 'Hypotension', 'Peripheral alpha 1- adrenergic receptor blocking agents (aka alpha 1- blockers) cause vasodilation and can produce marked hypotension, especially orthostatic hypotension with syncope or other postural symptoms such as dizziness, lightheadedness, and palpitations.  Orthostatic effects are most common during initiation of therapy and often occur within 90 minutes after the first dose.  However, they can also occur following a dosage increase or resumption of therapy after an interruption of more than a few days.  Agents with alpha 1a specificity, such as tamsulosin, act primarily on the prostate but are not devoid of hypotensive effects.  Therapy with peripheral alpha-1 blockers should be administered cautiously in patients with or predisposed to hypotensive or syncopal episodes.  Caution is also advised in patients who are dehydrated (e.g., due to severe or prolonged diarrhea or vomiting), since they may be more sensitive to the hypotensive effect of the drugs.  Therapy should be initiated with the lowest dosage possible and titrated gradually based on patient response and tolerance in accordance with the individual product package labeling.  During initiation or reinstitution of therapy and following an increase in dosage, patients should be advised not to rise abruptly from a sitting or recumbent position and to avoid situations where injury could result if syncope occur.  Concomitant use of alcohol, extensive periods of standing, prolonged or intense exercise, and exposure to heat can also precipitate orthostatic hypotension and should be minimized.  If dizziness, lightheadedness or palpitations occur, the patient should sit or lie down, and seek medical attention if symptoms are recurrent or bothersome.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26711, 31881, 'Tamsulosin', 'Hypotension', 'Peripheral alpha 1- adrenergic receptor blocking agents (aka alpha 1- blockers) cause vasodilation and can produce marked hypotension, especially orthostatic hypotension with syncope or other postural symptoms such as dizziness, lightheadedness, and palpitations.  Orthostatic effects are most common during initiation of therapy and often occur within 90 minutes after the first dose.  However, they can also occur following a dosage increase or resumption of therapy after an interruption of more than a few days.  Agents with alpha 1a specificity, such as tamsulosin, act primarily on the prostate but are not devoid of hypotensive effects.  Therapy with peripheral alpha-1 blockers should be administered cautiously in patients with or predisposed to hypotensive or syncopal episodes.  Caution is also advised in patients who are dehydrated (e.g., due to severe or prolonged diarrhea or vomiting), since they may be more sensitive to the hypotensive effect of the drugs.  Therapy should be initiated with the lowest dosage possible and titrated gradually based on patient response and tolerance in accordance with the individual product package labeling.  During initiation or reinstitution of therapy and following an increase in dosage, patients should be advised not to rise abruptly from a sitting or recumbent position and to avoid situations where injury could result if syncope occur.  Concomitant use of alcohol, extensive periods of standing, prolonged or intense exercise, and exposure to heat can also precipitate orthostatic hypotension and should be minimized.  If dizziness, lightheadedness or palpitations occur, the patient should sit or lie down, and seek medical attention if symptoms are recurrent or bothersome.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26712, 32696, 'Tamsulosin', 'Hypotension', 'Peripheral alpha 1- adrenergic receptor blocking agents (aka alpha 1- blockers) cause vasodilation and can produce marked hypotension, especially orthostatic hypotension with syncope or other postural symptoms such as dizziness, lightheadedness, and palpitations.  Orthostatic effects are most common during initiation of therapy and often occur within 90 minutes after the first dose.  However, they can also occur following a dosage increase or resumption of therapy after an interruption of more than a few days.  Agents with alpha 1a specificity, such as tamsulosin, act primarily on the prostate but are not devoid of hypotensive effects.  Therapy with peripheral alpha-1 blockers should be administered cautiously in patients with or predisposed to hypotensive or syncopal episodes.  Caution is also advised in patients who are dehydrated (e.g., due to severe or prolonged diarrhea or vomiting), since they may be more sensitive to the hypotensive effect of the drugs.  Therapy should be initiated with the lowest dosage possible and titrated gradually based on patient response and tolerance in accordance with the individual product package labeling.  During initiation or reinstitution of therapy and following an increase in dosage, patients should be advised not to rise abruptly from a sitting or recumbent position and to avoid situations where injury could result if syncope occur.  Concomitant use of alcohol, extensive periods of standing, prolonged or intense exercise, and exposure to heat can also precipitate orthostatic hypotension and should be minimized.  If dizziness, lightheadedness or palpitations occur, the patient should sit or lie down, and seek medical attention if symptoms are recurrent or bothersome.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26713, 3184, 'Tamsulosin', 'Kidney Failure, Chronic', 'Patients with renal impairment do not require an adjustment in tamsulosin dosing.  However, patients with end-stage renal disease (Clcr <10 mL/min) have not been studied.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26714, 6831, 'Tamsulosin', 'Kidney Failure, Chronic', 'Patients with renal impairment do not require an adjustment in tamsulosin dosing.  However, patients with end-stage renal disease (Clcr <10 mL/min) have not been studied.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26715, 9228, 'Tamsulosin', 'Kidney Failure, Chronic', 'Patients with renal impairment do not require an adjustment in tamsulosin dosing.  However, patients with end-stage renal disease (Clcr <10 mL/min) have not been studied.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26716, 9229, 'Tamsulosin', 'Kidney Failure, Chronic', 'Patients with renal impairment do not require an adjustment in tamsulosin dosing.  However, patients with end-stage renal disease (Clcr <10 mL/min) have not been studied.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26717, 11160, 'Tamsulosin', 'Kidney Failure, Chronic', 'Patients with renal impairment do not require an adjustment in tamsulosin dosing.  However, patients with end-stage renal disease (Clcr <10 mL/min) have not been studied.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26718, 11161, 'Tamsulosin', 'Kidney Failure, Chronic', 'Patients with renal impairment do not require an adjustment in tamsulosin dosing.  However, patients with end-stage renal disease (Clcr <10 mL/min) have not been studied.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26719, 11162, 'Tamsulosin', 'Kidney Failure, Chronic', 'Patients with renal impairment do not require an adjustment in tamsulosin dosing.  However, patients with end-stage renal disease (Clcr <10 mL/min) have not been studied.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26720, 15376, 'Tamsulosin', 'Kidney Failure, Chronic', 'Patients with renal impairment do not require an adjustment in tamsulosin dosing.  However, patients with end-stage renal disease (Clcr <10 mL/min) have not been studied.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26721, 16953, 'Tamsulosin', 'Kidney Failure, Chronic', 'Patients with renal impairment do not require an adjustment in tamsulosin dosing.  However, patients with end-stage renal disease (Clcr <10 mL/min) have not been studied.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26722, 21318, 'Tamsulosin', 'Kidney Failure, Chronic', 'Patients with renal impairment do not require an adjustment in tamsulosin dosing.  However, patients with end-stage renal disease (Clcr <10 mL/min) have not been studied.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26723, 22063, 'Tamsulosin', 'Kidney Failure, Chronic', 'Patients with renal impairment do not require an adjustment in tamsulosin dosing.  However, patients with end-stage renal disease (Clcr <10 mL/min) have not been studied.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26724, 22204, 'Tamsulosin', 'Kidney Failure, Chronic', 'Patients with renal impairment do not require an adjustment in tamsulosin dosing.  However, patients with end-stage renal disease (Clcr <10 mL/min) have not been studied.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26725, 27871, 'Tamsulosin', 'Kidney Failure, Chronic', 'Patients with renal impairment do not require an adjustment in tamsulosin dosing.  However, patients with end-stage renal disease (Clcr <10 mL/min) have not been studied.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26726, 27890, 'Tamsulosin', 'Kidney Failure, Chronic', 'Patients with renal impairment do not require an adjustment in tamsulosin dosing.  However, patients with end-stage renal disease (Clcr <10 mL/min) have not been studied.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26727, 31881, 'Tamsulosin', 'Kidney Failure, Chronic', 'Patients with renal impairment do not require an adjustment in tamsulosin dosing.  However, patients with end-stage renal disease (Clcr <10 mL/min) have not been studied.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26728, 32696, 'Tamsulosin', 'Kidney Failure, Chronic', 'Patients with renal impairment do not require an adjustment in tamsulosin dosing.  However, patients with end-stage renal disease (Clcr <10 mL/min) have not been studied.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26729, 3184, 'Tamsulosin', 'Liver Failure', 'Patients with moderate hepatic impairment do not require any adjustment in tamsulosin dosage.  Tamsulosin has not been studied in patients with severe hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26730, 6831, 'Tamsulosin', 'Liver Failure', 'Patients with moderate hepatic impairment do not require any adjustment in tamsulosin dosage.  Tamsulosin has not been studied in patients with severe hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26731, 9228, 'Tamsulosin', 'Liver Failure', 'Patients with moderate hepatic impairment do not require any adjustment in tamsulosin dosage.  Tamsulosin has not been studied in patients with severe hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26732, 9229, 'Tamsulosin', 'Liver Failure', 'Patients with moderate hepatic impairment do not require any adjustment in tamsulosin dosage.  Tamsulosin has not been studied in patients with severe hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26733, 11160, 'Tamsulosin', 'Liver Failure', 'Patients with moderate hepatic impairment do not require any adjustment in tamsulosin dosage.  Tamsulosin has not been studied in patients with severe hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26734, 11161, 'Tamsulosin', 'Liver Failure', 'Patients with moderate hepatic impairment do not require any adjustment in tamsulosin dosage.  Tamsulosin has not been studied in patients with severe hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26735, 11162, 'Tamsulosin', 'Liver Failure', 'Patients with moderate hepatic impairment do not require any adjustment in tamsulosin dosage.  Tamsulosin has not been studied in patients with severe hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26736, 15376, 'Tamsulosin', 'Liver Failure', 'Patients with moderate hepatic impairment do not require any adjustment in tamsulosin dosage.  Tamsulosin has not been studied in patients with severe hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26737, 16953, 'Tamsulosin', 'Liver Failure', 'Patients with moderate hepatic impairment do not require any adjustment in tamsulosin dosage.  Tamsulosin has not been studied in patients with severe hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26738, 21318, 'Tamsulosin', 'Liver Failure', 'Patients with moderate hepatic impairment do not require any adjustment in tamsulosin dosage.  Tamsulosin has not been studied in patients with severe hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26739, 22063, 'Tamsulosin', 'Liver Failure', 'Patients with moderate hepatic impairment do not require any adjustment in tamsulosin dosage.  Tamsulosin has not been studied in patients with severe hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26740, 22204, 'Tamsulosin', 'Liver Failure', 'Patients with moderate hepatic impairment do not require any adjustment in tamsulosin dosage.  Tamsulosin has not been studied in patients with severe hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26741, 27871, 'Tamsulosin', 'Liver Failure', 'Patients with moderate hepatic impairment do not require any adjustment in tamsulosin dosage.  Tamsulosin has not been studied in patients with severe hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26742, 27890, 'Tamsulosin', 'Liver Failure', 'Patients with moderate hepatic impairment do not require any adjustment in tamsulosin dosage.  Tamsulosin has not been studied in patients with severe hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26743, 31881, 'Tamsulosin', 'Liver Failure', 'Patients with moderate hepatic impairment do not require any adjustment in tamsulosin dosage.  Tamsulosin has not been studied in patients with severe hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26744, 32696, 'Tamsulosin', 'Liver Failure', 'Patients with moderate hepatic impairment do not require any adjustment in tamsulosin dosage.  Tamsulosin has not been studied in patients with severe hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26745, 11196, 'Tacrolimus', 'Diabetes Mellitus', 'Tacrolimus can induce post-transplant insulin-dependent diabetes mellitus (PTDM).  Temporary insulin therapy has been required in some patients, while long-term insulin use has been necessary in others.   Reversible insulin dependence has occurred in kidney and liver transplant patients.  PTDM has occurred in a greater percentage of tacrolimus-treated (20%) versus cyclosporine-treated (4%) kidney transplant patients.   Black and Hispanic patients are at increased risk for PTDM.  Therapy with tacrolimus should be administered cautiously in patients with pre-transplant diabetes mellitus.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26746, 13242, 'Tacrolimus', 'Diabetes Mellitus', 'Tacrolimus can induce post-transplant insulin-dependent diabetes mellitus (PTDM).  Temporary insulin therapy has been required in some patients, while long-term insulin use has been necessary in others.   Reversible insulin dependence has occurred in kidney and liver transplant patients.  PTDM has occurred in a greater percentage of tacrolimus-treated (20%) versus cyclosporine-treated (4%) kidney transplant patients.   Black and Hispanic patients are at increased risk for PTDM.  Therapy with tacrolimus should be administered cautiously in patients with pre-transplant diabetes mellitus.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26747, 13502, 'Tacrolimus', 'Diabetes Mellitus', 'Tacrolimus can induce post-transplant insulin-dependent diabetes mellitus (PTDM).  Temporary insulin therapy has been required in some patients, while long-term insulin use has been necessary in others.   Reversible insulin dependence has occurred in kidney and liver transplant patients.  PTDM has occurred in a greater percentage of tacrolimus-treated (20%) versus cyclosporine-treated (4%) kidney transplant patients.   Black and Hispanic patients are at increased risk for PTDM.  Therapy with tacrolimus should be administered cautiously in patients with pre-transplant diabetes mellitus.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26748, 13503, 'Tacrolimus', 'Diabetes Mellitus', 'Tacrolimus can induce post-transplant insulin-dependent diabetes mellitus (PTDM).  Temporary insulin therapy has been required in some patients, while long-term insulin use has been necessary in others.   Reversible insulin dependence has occurred in kidney and liver transplant patients.  PTDM has occurred in a greater percentage of tacrolimus-treated (20%) versus cyclosporine-treated (4%) kidney transplant patients.   Black and Hispanic patients are at increased risk for PTDM.  Therapy with tacrolimus should be administered cautiously in patients with pre-transplant diabetes mellitus.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26749, 13504, 'Tacrolimus', 'Diabetes Mellitus', 'Tacrolimus can induce post-transplant insulin-dependent diabetes mellitus (PTDM).  Temporary insulin therapy has been required in some patients, while long-term insulin use has been necessary in others.   Reversible insulin dependence has occurred in kidney and liver transplant patients.  PTDM has occurred in a greater percentage of tacrolimus-treated (20%) versus cyclosporine-treated (4%) kidney transplant patients.   Black and Hispanic patients are at increased risk for PTDM.  Therapy with tacrolimus should be administered cautiously in patients with pre-transplant diabetes mellitus.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26750, 13514, 'Tacrolimus', 'Diabetes Mellitus', 'Tacrolimus can induce post-transplant insulin-dependent diabetes mellitus (PTDM).  Temporary insulin therapy has been required in some patients, while long-term insulin use has been necessary in others.   Reversible insulin dependence has occurred in kidney and liver transplant patients.  PTDM has occurred in a greater percentage of tacrolimus-treated (20%) versus cyclosporine-treated (4%) kidney transplant patients.   Black and Hispanic patients are at increased risk for PTDM.  Therapy with tacrolimus should be administered cautiously in patients with pre-transplant diabetes mellitus.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26751, 13515, 'Tacrolimus', 'Diabetes Mellitus', 'Tacrolimus can induce post-transplant insulin-dependent diabetes mellitus (PTDM).  Temporary insulin therapy has been required in some patients, while long-term insulin use has been necessary in others.   Reversible insulin dependence has occurred in kidney and liver transplant patients.  PTDM has occurred in a greater percentage of tacrolimus-treated (20%) versus cyclosporine-treated (4%) kidney transplant patients.   Black and Hispanic patients are at increased risk for PTDM.  Therapy with tacrolimus should be administered cautiously in patients with pre-transplant diabetes mellitus.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26752, 13516, 'Tacrolimus', 'Diabetes Mellitus', 'Tacrolimus can induce post-transplant insulin-dependent diabetes mellitus (PTDM).  Temporary insulin therapy has been required in some patients, while long-term insulin use has been necessary in others.   Reversible insulin dependence has occurred in kidney and liver transplant patients.  PTDM has occurred in a greater percentage of tacrolimus-treated (20%) versus cyclosporine-treated (4%) kidney transplant patients.   Black and Hispanic patients are at increased risk for PTDM.  Therapy with tacrolimus should be administered cautiously in patients with pre-transplant diabetes mellitus.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26753, 13517, 'Tacrolimus', 'Diabetes Mellitus', 'Tacrolimus can induce post-transplant insulin-dependent diabetes mellitus (PTDM).  Temporary insulin therapy has been required in some patients, while long-term insulin use has been necessary in others.   Reversible insulin dependence has occurred in kidney and liver transplant patients.  PTDM has occurred in a greater percentage of tacrolimus-treated (20%) versus cyclosporine-treated (4%) kidney transplant patients.   Black and Hispanic patients are at increased risk for PTDM.  Therapy with tacrolimus should be administered cautiously in patients with pre-transplant diabetes mellitus.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26754, 13518, 'Tacrolimus', 'Diabetes Mellitus', 'Tacrolimus can induce post-transplant insulin-dependent diabetes mellitus (PTDM).  Temporary insulin therapy has been required in some patients, while long-term insulin use has been necessary in others.   Reversible insulin dependence has occurred in kidney and liver transplant patients.  PTDM has occurred in a greater percentage of tacrolimus-treated (20%) versus cyclosporine-treated (4%) kidney transplant patients.   Black and Hispanic patients are at increased risk for PTDM.  Therapy with tacrolimus should be administered cautiously in patients with pre-transplant diabetes mellitus.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26755, 13519, 'Tacrolimus', 'Diabetes Mellitus', 'Tacrolimus can induce post-transplant insulin-dependent diabetes mellitus (PTDM).  Temporary insulin therapy has been required in some patients, while long-term insulin use has been necessary in others.   Reversible insulin dependence has occurred in kidney and liver transplant patients.  PTDM has occurred in a greater percentage of tacrolimus-treated (20%) versus cyclosporine-treated (4%) kidney transplant patients.   Black and Hispanic patients are at increased risk for PTDM.  Therapy with tacrolimus should be administered cautiously in patients with pre-transplant diabetes mellitus.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26756, 13520, 'Tacrolimus', 'Diabetes Mellitus', 'Tacrolimus can induce post-transplant insulin-dependent diabetes mellitus (PTDM).  Temporary insulin therapy has been required in some patients, while long-term insulin use has been necessary in others.   Reversible insulin dependence has occurred in kidney and liver transplant patients.  PTDM has occurred in a greater percentage of tacrolimus-treated (20%) versus cyclosporine-treated (4%) kidney transplant patients.   Black and Hispanic patients are at increased risk for PTDM.  Therapy with tacrolimus should be administered cautiously in patients with pre-transplant diabetes mellitus.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26757, 13521, 'Tacrolimus', 'Diabetes Mellitus', 'Tacrolimus can induce post-transplant insulin-dependent diabetes mellitus (PTDM).  Temporary insulin therapy has been required in some patients, while long-term insulin use has been necessary in others.   Reversible insulin dependence has occurred in kidney and liver transplant patients.  PTDM has occurred in a greater percentage of tacrolimus-treated (20%) versus cyclosporine-treated (4%) kidney transplant patients.   Black and Hispanic patients are at increased risk for PTDM.  Therapy with tacrolimus should be administered cautiously in patients with pre-transplant diabetes mellitus.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26758, 25434, 'Tacrolimus', 'Diabetes Mellitus', 'Tacrolimus can induce post-transplant insulin-dependent diabetes mellitus (PTDM).  Temporary insulin therapy has been required in some patients, while long-term insulin use has been necessary in others.   Reversible insulin dependence has occurred in kidney and liver transplant patients.  PTDM has occurred in a greater percentage of tacrolimus-treated (20%) versus cyclosporine-treated (4%) kidney transplant patients.   Black and Hispanic patients are at increased risk for PTDM.  Therapy with tacrolimus should be administered cautiously in patients with pre-transplant diabetes mellitus.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26759, 28422, 'Tacrolimus', 'Diabetes Mellitus', 'Tacrolimus can induce post-transplant insulin-dependent diabetes mellitus (PTDM).  Temporary insulin therapy has been required in some patients, while long-term insulin use has been necessary in others.   Reversible insulin dependence has occurred in kidney and liver transplant patients.  PTDM has occurred in a greater percentage of tacrolimus-treated (20%) versus cyclosporine-treated (4%) kidney transplant patients.   Black and Hispanic patients are at increased risk for PTDM.  Therapy with tacrolimus should be administered cautiously in patients with pre-transplant diabetes mellitus.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26760, 29518, 'Tacrolimus', 'Diabetes Mellitus', 'Tacrolimus can induce post-transplant insulin-dependent diabetes mellitus (PTDM).  Temporary insulin therapy has been required in some patients, while long-term insulin use has been necessary in others.   Reversible insulin dependence has occurred in kidney and liver transplant patients.  PTDM has occurred in a greater percentage of tacrolimus-treated (20%) versus cyclosporine-treated (4%) kidney transplant patients.   Black and Hispanic patients are at increased risk for PTDM.  Therapy with tacrolimus should be administered cautiously in patients with pre-transplant diabetes mellitus.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26761, 11196, 'Tacrolimus', 'Liver Diseases', 'Tacrolimus undergoes significant hepatic metabolism, primarily by CYP450 3A enzymes.  Less than 5% of tacrolimus is eliminated unchanged in the bile and <1% is eliminated unchanged in the urine.  Moderate or severe hepatic dysfunction or impaired post-transplant hepatic function may alter the metabolic and therapeutic activity of tacrolimus and increase the whole blood tacrolimus concentration.  Therapy with tacrolimus should be administered cautiously and dosage adjustments considered in the presence of moderate or severe hepatic impairment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26762, 13242, 'Tacrolimus', 'Liver Diseases', 'Tacrolimus undergoes significant hepatic metabolism, primarily by CYP450 3A enzymes.  Less than 5% of tacrolimus is eliminated unchanged in the bile and <1% is eliminated unchanged in the urine.  Moderate or severe hepatic dysfunction or impaired post-transplant hepatic function may alter the metabolic and therapeutic activity of tacrolimus and increase the whole blood tacrolimus concentration.  Therapy with tacrolimus should be administered cautiously and dosage adjustments considered in the presence of moderate or severe hepatic impairment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26763, 13502, 'Tacrolimus', 'Liver Diseases', 'Tacrolimus undergoes significant hepatic metabolism, primarily by CYP450 3A enzymes.  Less than 5% of tacrolimus is eliminated unchanged in the bile and <1% is eliminated unchanged in the urine.  Moderate or severe hepatic dysfunction or impaired post-transplant hepatic function may alter the metabolic and therapeutic activity of tacrolimus and increase the whole blood tacrolimus concentration.  Therapy with tacrolimus should be administered cautiously and dosage adjustments considered in the presence of moderate or severe hepatic impairment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26764, 13503, 'Tacrolimus', 'Liver Diseases', 'Tacrolimus undergoes significant hepatic metabolism, primarily by CYP450 3A enzymes.  Less than 5% of tacrolimus is eliminated unchanged in the bile and <1% is eliminated unchanged in the urine.  Moderate or severe hepatic dysfunction or impaired post-transplant hepatic function may alter the metabolic and therapeutic activity of tacrolimus and increase the whole blood tacrolimus concentration.  Therapy with tacrolimus should be administered cautiously and dosage adjustments considered in the presence of moderate or severe hepatic impairment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26765, 13504, 'Tacrolimus', 'Liver Diseases', 'Tacrolimus undergoes significant hepatic metabolism, primarily by CYP450 3A enzymes.  Less than 5% of tacrolimus is eliminated unchanged in the bile and <1% is eliminated unchanged in the urine.  Moderate or severe hepatic dysfunction or impaired post-transplant hepatic function may alter the metabolic and therapeutic activity of tacrolimus and increase the whole blood tacrolimus concentration.  Therapy with tacrolimus should be administered cautiously and dosage adjustments considered in the presence of moderate or severe hepatic impairment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26766, 13514, 'Tacrolimus', 'Liver Diseases', 'Tacrolimus undergoes significant hepatic metabolism, primarily by CYP450 3A enzymes.  Less than 5% of tacrolimus is eliminated unchanged in the bile and <1% is eliminated unchanged in the urine.  Moderate or severe hepatic dysfunction or impaired post-transplant hepatic function may alter the metabolic and therapeutic activity of tacrolimus and increase the whole blood tacrolimus concentration.  Therapy with tacrolimus should be administered cautiously and dosage adjustments considered in the presence of moderate or severe hepatic impairment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26767, 13515, 'Tacrolimus', 'Liver Diseases', 'Tacrolimus undergoes significant hepatic metabolism, primarily by CYP450 3A enzymes.  Less than 5% of tacrolimus is eliminated unchanged in the bile and <1% is eliminated unchanged in the urine.  Moderate or severe hepatic dysfunction or impaired post-transplant hepatic function may alter the metabolic and therapeutic activity of tacrolimus and increase the whole blood tacrolimus concentration.  Therapy with tacrolimus should be administered cautiously and dosage adjustments considered in the presence of moderate or severe hepatic impairment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26768, 13516, 'Tacrolimus', 'Liver Diseases', 'Tacrolimus undergoes significant hepatic metabolism, primarily by CYP450 3A enzymes.  Less than 5% of tacrolimus is eliminated unchanged in the bile and <1% is eliminated unchanged in the urine.  Moderate or severe hepatic dysfunction or impaired post-transplant hepatic function may alter the metabolic and therapeutic activity of tacrolimus and increase the whole blood tacrolimus concentration.  Therapy with tacrolimus should be administered cautiously and dosage adjustments considered in the presence of moderate or severe hepatic impairment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26769, 13517, 'Tacrolimus', 'Liver Diseases', 'Tacrolimus undergoes significant hepatic metabolism, primarily by CYP450 3A enzymes.  Less than 5% of tacrolimus is eliminated unchanged in the bile and <1% is eliminated unchanged in the urine.  Moderate or severe hepatic dysfunction or impaired post-transplant hepatic function may alter the metabolic and therapeutic activity of tacrolimus and increase the whole blood tacrolimus concentration.  Therapy with tacrolimus should be administered cautiously and dosage adjustments considered in the presence of moderate or severe hepatic impairment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26770, 13518, 'Tacrolimus', 'Liver Diseases', 'Tacrolimus undergoes significant hepatic metabolism, primarily by CYP450 3A enzymes.  Less than 5% of tacrolimus is eliminated unchanged in the bile and <1% is eliminated unchanged in the urine.  Moderate or severe hepatic dysfunction or impaired post-transplant hepatic function may alter the metabolic and therapeutic activity of tacrolimus and increase the whole blood tacrolimus concentration.  Therapy with tacrolimus should be administered cautiously and dosage adjustments considered in the presence of moderate or severe hepatic impairment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26771, 13519, 'Tacrolimus', 'Liver Diseases', 'Tacrolimus undergoes significant hepatic metabolism, primarily by CYP450 3A enzymes.  Less than 5% of tacrolimus is eliminated unchanged in the bile and <1% is eliminated unchanged in the urine.  Moderate or severe hepatic dysfunction or impaired post-transplant hepatic function may alter the metabolic and therapeutic activity of tacrolimus and increase the whole blood tacrolimus concentration.  Therapy with tacrolimus should be administered cautiously and dosage adjustments considered in the presence of moderate or severe hepatic impairment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26772, 13520, 'Tacrolimus', 'Liver Diseases', 'Tacrolimus undergoes significant hepatic metabolism, primarily by CYP450 3A enzymes.  Less than 5% of tacrolimus is eliminated unchanged in the bile and <1% is eliminated unchanged in the urine.  Moderate or severe hepatic dysfunction or impaired post-transplant hepatic function may alter the metabolic and therapeutic activity of tacrolimus and increase the whole blood tacrolimus concentration.  Therapy with tacrolimus should be administered cautiously and dosage adjustments considered in the presence of moderate or severe hepatic impairment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26773, 13521, 'Tacrolimus', 'Liver Diseases', 'Tacrolimus undergoes significant hepatic metabolism, primarily by CYP450 3A enzymes.  Less than 5% of tacrolimus is eliminated unchanged in the bile and <1% is eliminated unchanged in the urine.  Moderate or severe hepatic dysfunction or impaired post-transplant hepatic function may alter the metabolic and therapeutic activity of tacrolimus and increase the whole blood tacrolimus concentration.  Therapy with tacrolimus should be administered cautiously and dosage adjustments considered in the presence of moderate or severe hepatic impairment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26774, 25434, 'Tacrolimus', 'Liver Diseases', 'Tacrolimus undergoes significant hepatic metabolism, primarily by CYP450 3A enzymes.  Less than 5% of tacrolimus is eliminated unchanged in the bile and <1% is eliminated unchanged in the urine.  Moderate or severe hepatic dysfunction or impaired post-transplant hepatic function may alter the metabolic and therapeutic activity of tacrolimus and increase the whole blood tacrolimus concentration.  Therapy with tacrolimus should be administered cautiously and dosage adjustments considered in the presence of moderate or severe hepatic impairment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26775, 28422, 'Tacrolimus', 'Liver Diseases', 'Tacrolimus undergoes significant hepatic metabolism, primarily by CYP450 3A enzymes.  Less than 5% of tacrolimus is eliminated unchanged in the bile and <1% is eliminated unchanged in the urine.  Moderate or severe hepatic dysfunction or impaired post-transplant hepatic function may alter the metabolic and therapeutic activity of tacrolimus and increase the whole blood tacrolimus concentration.  Therapy with tacrolimus should be administered cautiously and dosage adjustments considered in the presence of moderate or severe hepatic impairment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26776, 29518, 'Tacrolimus', 'Liver Diseases', 'Tacrolimus undergoes significant hepatic metabolism, primarily by CYP450 3A enzymes.  Less than 5% of tacrolimus is eliminated unchanged in the bile and <1% is eliminated unchanged in the urine.  Moderate or severe hepatic dysfunction or impaired post-transplant hepatic function may alter the metabolic and therapeutic activity of tacrolimus and increase the whole blood tacrolimus concentration.  Therapy with tacrolimus should be administered cautiously and dosage adjustments considered in the presence of moderate or severe hepatic impairment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26777, 11196, 'Tacrolimus', 'Infections', 'Due to immunosuppression, patients receiving tacrolimus are at increased risk for infections, including polyoma virus infections, post-transplant lymphoproliferative disorder (PTLD) and CMV viremia and CMV disease.  Polyoma virus infections in transplant patients may have serious, and sometimes fatal, outcomes.  These include polyoma virus-associated nephropathy (PVAN), mostly due to BK virus infection, and JC virus-associated progressive multifocal leukoencephalopathy (PML).  Cases of PML have been reported in patients treated with tacrolimus.  Risk factors for PML include treatment with immunosuppressant therapies and impairment of immune function.  PTLD associated with Epstein-Barr Virus (EBV), has been reported in immunosuppressed organ transplant patients.  Patients that are Epstein-Barr Virus (EBV) seronegative appears to have the greatest risk of developing PTLD.  It is recommended to monitor EBV serology during tacrolimus therapy.  Caution and patient monitoring is recommended when using this drug in immunosuppressed patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26778, 13242, 'Tacrolimus', 'Infections', 'Due to immunosuppression, patients receiving tacrolimus are at increased risk for infections, including polyoma virus infections, post-transplant lymphoproliferative disorder (PTLD) and CMV viremia and CMV disease.  Polyoma virus infections in transplant patients may have serious, and sometimes fatal, outcomes.  These include polyoma virus-associated nephropathy (PVAN), mostly due to BK virus infection, and JC virus-associated progressive multifocal leukoencephalopathy (PML).  Cases of PML have been reported in patients treated with tacrolimus.  Risk factors for PML include treatment with immunosuppressant therapies and impairment of immune function.  PTLD associated with Epstein-Barr Virus (EBV), has been reported in immunosuppressed organ transplant patients.  Patients that are Epstein-Barr Virus (EBV) seronegative appears to have the greatest risk of developing PTLD.  It is recommended to monitor EBV serology during tacrolimus therapy.  Caution and patient monitoring is recommended when using this drug in immunosuppressed patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26779, 13502, 'Tacrolimus', 'Infections', 'Due to immunosuppression, patients receiving tacrolimus are at increased risk for infections, including polyoma virus infections, post-transplant lymphoproliferative disorder (PTLD) and CMV viremia and CMV disease.  Polyoma virus infections in transplant patients may have serious, and sometimes fatal, outcomes.  These include polyoma virus-associated nephropathy (PVAN), mostly due to BK virus infection, and JC virus-associated progressive multifocal leukoencephalopathy (PML).  Cases of PML have been reported in patients treated with tacrolimus.  Risk factors for PML include treatment with immunosuppressant therapies and impairment of immune function.  PTLD associated with Epstein-Barr Virus (EBV), has been reported in immunosuppressed organ transplant patients.  Patients that are Epstein-Barr Virus (EBV) seronegative appears to have the greatest risk of developing PTLD.  It is recommended to monitor EBV serology during tacrolimus therapy.  Caution and patient monitoring is recommended when using this drug in immunosuppressed patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26780, 13503, 'Tacrolimus', 'Infections', 'Due to immunosuppression, patients receiving tacrolimus are at increased risk for infections, including polyoma virus infections, post-transplant lymphoproliferative disorder (PTLD) and CMV viremia and CMV disease.  Polyoma virus infections in transplant patients may have serious, and sometimes fatal, outcomes.  These include polyoma virus-associated nephropathy (PVAN), mostly due to BK virus infection, and JC virus-associated progressive multifocal leukoencephalopathy (PML).  Cases of PML have been reported in patients treated with tacrolimus.  Risk factors for PML include treatment with immunosuppressant therapies and impairment of immune function.  PTLD associated with Epstein-Barr Virus (EBV), has been reported in immunosuppressed organ transplant patients.  Patients that are Epstein-Barr Virus (EBV) seronegative appears to have the greatest risk of developing PTLD.  It is recommended to monitor EBV serology during tacrolimus therapy.  Caution and patient monitoring is recommended when using this drug in immunosuppressed patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26781, 13504, 'Tacrolimus', 'Infections', 'Due to immunosuppression, patients receiving tacrolimus are at increased risk for infections, including polyoma virus infections, post-transplant lymphoproliferative disorder (PTLD) and CMV viremia and CMV disease.  Polyoma virus infections in transplant patients may have serious, and sometimes fatal, outcomes.  These include polyoma virus-associated nephropathy (PVAN), mostly due to BK virus infection, and JC virus-associated progressive multifocal leukoencephalopathy (PML).  Cases of PML have been reported in patients treated with tacrolimus.  Risk factors for PML include treatment with immunosuppressant therapies and impairment of immune function.  PTLD associated with Epstein-Barr Virus (EBV), has been reported in immunosuppressed organ transplant patients.  Patients that are Epstein-Barr Virus (EBV) seronegative appears to have the greatest risk of developing PTLD.  It is recommended to monitor EBV serology during tacrolimus therapy.  Caution and patient monitoring is recommended when using this drug in immunosuppressed patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26782, 13514, 'Tacrolimus', 'Infections', 'Due to immunosuppression, patients receiving tacrolimus are at increased risk for infections, including polyoma virus infections, post-transplant lymphoproliferative disorder (PTLD) and CMV viremia and CMV disease.  Polyoma virus infections in transplant patients may have serious, and sometimes fatal, outcomes.  These include polyoma virus-associated nephropathy (PVAN), mostly due to BK virus infection, and JC virus-associated progressive multifocal leukoencephalopathy (PML).  Cases of PML have been reported in patients treated with tacrolimus.  Risk factors for PML include treatment with immunosuppressant therapies and impairment of immune function.  PTLD associated with Epstein-Barr Virus (EBV), has been reported in immunosuppressed organ transplant patients.  Patients that are Epstein-Barr Virus (EBV) seronegative appears to have the greatest risk of developing PTLD.  It is recommended to monitor EBV serology during tacrolimus therapy.  Caution and patient monitoring is recommended when using this drug in immunosuppressed patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26783, 13515, 'Tacrolimus', 'Infections', 'Due to immunosuppression, patients receiving tacrolimus are at increased risk for infections, including polyoma virus infections, post-transplant lymphoproliferative disorder (PTLD) and CMV viremia and CMV disease.  Polyoma virus infections in transplant patients may have serious, and sometimes fatal, outcomes.  These include polyoma virus-associated nephropathy (PVAN), mostly due to BK virus infection, and JC virus-associated progressive multifocal leukoencephalopathy (PML).  Cases of PML have been reported in patients treated with tacrolimus.  Risk factors for PML include treatment with immunosuppressant therapies and impairment of immune function.  PTLD associated with Epstein-Barr Virus (EBV), has been reported in immunosuppressed organ transplant patients.  Patients that are Epstein-Barr Virus (EBV) seronegative appears to have the greatest risk of developing PTLD.  It is recommended to monitor EBV serology during tacrolimus therapy.  Caution and patient monitoring is recommended when using this drug in immunosuppressed patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26784, 13516, 'Tacrolimus', 'Infections', 'Due to immunosuppression, patients receiving tacrolimus are at increased risk for infections, including polyoma virus infections, post-transplant lymphoproliferative disorder (PTLD) and CMV viremia and CMV disease.  Polyoma virus infections in transplant patients may have serious, and sometimes fatal, outcomes.  These include polyoma virus-associated nephropathy (PVAN), mostly due to BK virus infection, and JC virus-associated progressive multifocal leukoencephalopathy (PML).  Cases of PML have been reported in patients treated with tacrolimus.  Risk factors for PML include treatment with immunosuppressant therapies and impairment of immune function.  PTLD associated with Epstein-Barr Virus (EBV), has been reported in immunosuppressed organ transplant patients.  Patients that are Epstein-Barr Virus (EBV) seronegative appears to have the greatest risk of developing PTLD.  It is recommended to monitor EBV serology during tacrolimus therapy.  Caution and patient monitoring is recommended when using this drug in immunosuppressed patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26785, 13517, 'Tacrolimus', 'Infections', 'Due to immunosuppression, patients receiving tacrolimus are at increased risk for infections, including polyoma virus infections, post-transplant lymphoproliferative disorder (PTLD) and CMV viremia and CMV disease.  Polyoma virus infections in transplant patients may have serious, and sometimes fatal, outcomes.  These include polyoma virus-associated nephropathy (PVAN), mostly due to BK virus infection, and JC virus-associated progressive multifocal leukoencephalopathy (PML).  Cases of PML have been reported in patients treated with tacrolimus.  Risk factors for PML include treatment with immunosuppressant therapies and impairment of immune function.  PTLD associated with Epstein-Barr Virus (EBV), has been reported in immunosuppressed organ transplant patients.  Patients that are Epstein-Barr Virus (EBV) seronegative appears to have the greatest risk of developing PTLD.  It is recommended to monitor EBV serology during tacrolimus therapy.  Caution and patient monitoring is recommended when using this drug in immunosuppressed patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26786, 13518, 'Tacrolimus', 'Infections', 'Due to immunosuppression, patients receiving tacrolimus are at increased risk for infections, including polyoma virus infections, post-transplant lymphoproliferative disorder (PTLD) and CMV viremia and CMV disease.  Polyoma virus infections in transplant patients may have serious, and sometimes fatal, outcomes.  These include polyoma virus-associated nephropathy (PVAN), mostly due to BK virus infection, and JC virus-associated progressive multifocal leukoencephalopathy (PML).  Cases of PML have been reported in patients treated with tacrolimus.  Risk factors for PML include treatment with immunosuppressant therapies and impairment of immune function.  PTLD associated with Epstein-Barr Virus (EBV), has been reported in immunosuppressed organ transplant patients.  Patients that are Epstein-Barr Virus (EBV) seronegative appears to have the greatest risk of developing PTLD.  It is recommended to monitor EBV serology during tacrolimus therapy.  Caution and patient monitoring is recommended when using this drug in immunosuppressed patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26787, 13519, 'Tacrolimus', 'Infections', 'Due to immunosuppression, patients receiving tacrolimus are at increased risk for infections, including polyoma virus infections, post-transplant lymphoproliferative disorder (PTLD) and CMV viremia and CMV disease.  Polyoma virus infections in transplant patients may have serious, and sometimes fatal, outcomes.  These include polyoma virus-associated nephropathy (PVAN), mostly due to BK virus infection, and JC virus-associated progressive multifocal leukoencephalopathy (PML).  Cases of PML have been reported in patients treated with tacrolimus.  Risk factors for PML include treatment with immunosuppressant therapies and impairment of immune function.  PTLD associated with Epstein-Barr Virus (EBV), has been reported in immunosuppressed organ transplant patients.  Patients that are Epstein-Barr Virus (EBV) seronegative appears to have the greatest risk of developing PTLD.  It is recommended to monitor EBV serology during tacrolimus therapy.  Caution and patient monitoring is recommended when using this drug in immunosuppressed patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26788, 13520, 'Tacrolimus', 'Infections', 'Due to immunosuppression, patients receiving tacrolimus are at increased risk for infections, including polyoma virus infections, post-transplant lymphoproliferative disorder (PTLD) and CMV viremia and CMV disease.  Polyoma virus infections in transplant patients may have serious, and sometimes fatal, outcomes.  These include polyoma virus-associated nephropathy (PVAN), mostly due to BK virus infection, and JC virus-associated progressive multifocal leukoencephalopathy (PML).  Cases of PML have been reported in patients treated with tacrolimus.  Risk factors for PML include treatment with immunosuppressant therapies and impairment of immune function.  PTLD associated with Epstein-Barr Virus (EBV), has been reported in immunosuppressed organ transplant patients.  Patients that are Epstein-Barr Virus (EBV) seronegative appears to have the greatest risk of developing PTLD.  It is recommended to monitor EBV serology during tacrolimus therapy.  Caution and patient monitoring is recommended when using this drug in immunosuppressed patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26789, 13521, 'Tacrolimus', 'Infections', 'Due to immunosuppression, patients receiving tacrolimus are at increased risk for infections, including polyoma virus infections, post-transplant lymphoproliferative disorder (PTLD) and CMV viremia and CMV disease.  Polyoma virus infections in transplant patients may have serious, and sometimes fatal, outcomes.  These include polyoma virus-associated nephropathy (PVAN), mostly due to BK virus infection, and JC virus-associated progressive multifocal leukoencephalopathy (PML).  Cases of PML have been reported in patients treated with tacrolimus.  Risk factors for PML include treatment with immunosuppressant therapies and impairment of immune function.  PTLD associated with Epstein-Barr Virus (EBV), has been reported in immunosuppressed organ transplant patients.  Patients that are Epstein-Barr Virus (EBV) seronegative appears to have the greatest risk of developing PTLD.  It is recommended to monitor EBV serology during tacrolimus therapy.  Caution and patient monitoring is recommended when using this drug in immunosuppressed patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26790, 25434, 'Tacrolimus', 'Infections', 'Due to immunosuppression, patients receiving tacrolimus are at increased risk for infections, including polyoma virus infections, post-transplant lymphoproliferative disorder (PTLD) and CMV viremia and CMV disease.  Polyoma virus infections in transplant patients may have serious, and sometimes fatal, outcomes.  These include polyoma virus-associated nephropathy (PVAN), mostly due to BK virus infection, and JC virus-associated progressive multifocal leukoencephalopathy (PML).  Cases of PML have been reported in patients treated with tacrolimus.  Risk factors for PML include treatment with immunosuppressant therapies and impairment of immune function.  PTLD associated with Epstein-Barr Virus (EBV), has been reported in immunosuppressed organ transplant patients.  Patients that are Epstein-Barr Virus (EBV) seronegative appears to have the greatest risk of developing PTLD.  It is recommended to monitor EBV serology during tacrolimus therapy.  Caution and patient monitoring is recommended when using this drug in immunosuppressed patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26791, 28422, 'Tacrolimus', 'Infections', 'Due to immunosuppression, patients receiving tacrolimus are at increased risk for infections, including polyoma virus infections, post-transplant lymphoproliferative disorder (PTLD) and CMV viremia and CMV disease.  Polyoma virus infections in transplant patients may have serious, and sometimes fatal, outcomes.  These include polyoma virus-associated nephropathy (PVAN), mostly due to BK virus infection, and JC virus-associated progressive multifocal leukoencephalopathy (PML).  Cases of PML have been reported in patients treated with tacrolimus.  Risk factors for PML include treatment with immunosuppressant therapies and impairment of immune function.  PTLD associated with Epstein-Barr Virus (EBV), has been reported in immunosuppressed organ transplant patients.  Patients that are Epstein-Barr Virus (EBV) seronegative appears to have the greatest risk of developing PTLD.  It is recommended to monitor EBV serology during tacrolimus therapy.  Caution and patient monitoring is recommended when using this drug in immunosuppressed patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26792, 29518, 'Tacrolimus', 'Infections', 'Due to immunosuppression, patients receiving tacrolimus are at increased risk for infections, including polyoma virus infections, post-transplant lymphoproliferative disorder (PTLD) and CMV viremia and CMV disease.  Polyoma virus infections in transplant patients may have serious, and sometimes fatal, outcomes.  These include polyoma virus-associated nephropathy (PVAN), mostly due to BK virus infection, and JC virus-associated progressive multifocal leukoencephalopathy (PML).  Cases of PML have been reported in patients treated with tacrolimus.  Risk factors for PML include treatment with immunosuppressant therapies and impairment of immune function.  PTLD associated with Epstein-Barr Virus (EBV), has been reported in immunosuppressed organ transplant patients.  Patients that are Epstein-Barr Virus (EBV) seronegative appears to have the greatest risk of developing PTLD.  It is recommended to monitor EBV serology during tacrolimus therapy.  Caution and patient monitoring is recommended when using this drug in immunosuppressed patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26793, 11196, 'Tacrolimus', 'Long QT Syndrome', 'Tacrolimus may prolong the QT/QTc interval and may cause Torsade de Pointes.  It is recommended to avoid tacrolimus in patients with congenital long QT syndrome.  In patients with congestive heart failure, bradyarrhythmias, those taking certain antiarrhythmic medications or other medicinal products that lead to QT prolongation, and those with electrolyte disturbances such as hypokalemia, hypocalcemia, or hypomagnesemia, consider monitoring of tacrolimus whole blood concentrations and obtaining electrocardiograms and monitoring electrolytes (magnesium, potassium, calcium) periodically during treatment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26794, 13242, 'Tacrolimus', 'Long QT Syndrome', 'Tacrolimus may prolong the QT/QTc interval and may cause Torsade de Pointes.  It is recommended to avoid tacrolimus in patients with congenital long QT syndrome.  In patients with congestive heart failure, bradyarrhythmias, those taking certain antiarrhythmic medications or other medicinal products that lead to QT prolongation, and those with electrolyte disturbances such as hypokalemia, hypocalcemia, or hypomagnesemia, consider monitoring of tacrolimus whole blood concentrations and obtaining electrocardiograms and monitoring electrolytes (magnesium, potassium, calcium) periodically during treatment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26795, 13502, 'Tacrolimus', 'Long QT Syndrome', 'Tacrolimus may prolong the QT/QTc interval and may cause Torsade de Pointes.  It is recommended to avoid tacrolimus in patients with congenital long QT syndrome.  In patients with congestive heart failure, bradyarrhythmias, those taking certain antiarrhythmic medications or other medicinal products that lead to QT prolongation, and those with electrolyte disturbances such as hypokalemia, hypocalcemia, or hypomagnesemia, consider monitoring of tacrolimus whole blood concentrations and obtaining electrocardiograms and monitoring electrolytes (magnesium, potassium, calcium) periodically during treatment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26796, 13503, 'Tacrolimus', 'Long QT Syndrome', 'Tacrolimus may prolong the QT/QTc interval and may cause Torsade de Pointes.  It is recommended to avoid tacrolimus in patients with congenital long QT syndrome.  In patients with congestive heart failure, bradyarrhythmias, those taking certain antiarrhythmic medications or other medicinal products that lead to QT prolongation, and those with electrolyte disturbances such as hypokalemia, hypocalcemia, or hypomagnesemia, consider monitoring of tacrolimus whole blood concentrations and obtaining electrocardiograms and monitoring electrolytes (magnesium, potassium, calcium) periodically during treatment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26797, 13504, 'Tacrolimus', 'Long QT Syndrome', 'Tacrolimus may prolong the QT/QTc interval and may cause Torsade de Pointes.  It is recommended to avoid tacrolimus in patients with congenital long QT syndrome.  In patients with congestive heart failure, bradyarrhythmias, those taking certain antiarrhythmic medications or other medicinal products that lead to QT prolongation, and those with electrolyte disturbances such as hypokalemia, hypocalcemia, or hypomagnesemia, consider monitoring of tacrolimus whole blood concentrations and obtaining electrocardiograms and monitoring electrolytes (magnesium, potassium, calcium) periodically during treatment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26798, 13514, 'Tacrolimus', 'Long QT Syndrome', 'Tacrolimus may prolong the QT/QTc interval and may cause Torsade de Pointes.  It is recommended to avoid tacrolimus in patients with congenital long QT syndrome.  In patients with congestive heart failure, bradyarrhythmias, those taking certain antiarrhythmic medications or other medicinal products that lead to QT prolongation, and those with electrolyte disturbances such as hypokalemia, hypocalcemia, or hypomagnesemia, consider monitoring of tacrolimus whole blood concentrations and obtaining electrocardiograms and monitoring electrolytes (magnesium, potassium, calcium) periodically during treatment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26799, 13515, 'Tacrolimus', 'Long QT Syndrome', 'Tacrolimus may prolong the QT/QTc interval and may cause Torsade de Pointes.  It is recommended to avoid tacrolimus in patients with congenital long QT syndrome.  In patients with congestive heart failure, bradyarrhythmias, those taking certain antiarrhythmic medications or other medicinal products that lead to QT prolongation, and those with electrolyte disturbances such as hypokalemia, hypocalcemia, or hypomagnesemia, consider monitoring of tacrolimus whole blood concentrations and obtaining electrocardiograms and monitoring electrolytes (magnesium, potassium, calcium) periodically during treatment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26800, 13516, 'Tacrolimus', 'Long QT Syndrome', 'Tacrolimus may prolong the QT/QTc interval and may cause Torsade de Pointes.  It is recommended to avoid tacrolimus in patients with congenital long QT syndrome.  In patients with congestive heart failure, bradyarrhythmias, those taking certain antiarrhythmic medications or other medicinal products that lead to QT prolongation, and those with electrolyte disturbances such as hypokalemia, hypocalcemia, or hypomagnesemia, consider monitoring of tacrolimus whole blood concentrations and obtaining electrocardiograms and monitoring electrolytes (magnesium, potassium, calcium) periodically during treatment.', '3', '', 'DDInter', 0);
